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OBJECTIVES The aim of this study was to investigate whether the caspase-3 inhibitor Ac-DEVD-CHO
functionally improves stunned myocardium.
BACKGROUND Degradation of troponin I contributes to the pathogenesis of myocardial stunning, whereas
the role of apoptosis is unknown. Caspase-3 is an essential apoptotic protease that is
specifically inhibited by Ac-DEVD-CHO.
METHODS Isolated working hearts of rats were exposed to 30 min of low-flow ischemia, followed by 30
min of reperfusion. Ac-DEVD-CHO (0.1 to 1 mol/l) was added 15 min before
ischemia/reperfusion or 5 min before reperfusion. Cardiac output, external heart power, left
ventricular (LV) developing pressure and contractility (dp/dtmax) were measured. Apoptosis
was assessed by TUNEL staining and internucleosomal deoxyribonucleic acid fragmentation.
Caspase-3 processing and troponin I cleavage were determined by immunoblotting.
Caspase-3 activity was measured using a fluorogenic substrate.
RESULTS The addition of Ac-DEVD-CHO before ischemia/reperfusion or before reperfusion dose-
dependently and significantly (p  0.05) improved post-ischemic recovery of cardiac output,
external heart power, LV developing pressure and dp/dtmax, compared with the vehicle
(0.01% dimethyl sulfoxide). Ac-DEVD-CHO was similarly effective when given before
reperfusion. Ac-DEVD-CHO blocked ischemia/reperfusion-induced caspase-3 activation,
but cardiomyocyte apoptosis was unaffected. Troponin I cleavage was not inhibited by
Ac-DEVD-CHO.
CONCLUSIONS Caspase-3 is activated in stunned myocardium. Inhibition of caspase-3 by Ac-DEVD-CHO
significantly improves post-ischemic contractile recovery of stunned myocardium, even when
given after the onset of ischemia. The mechanism(s) of protection by Ac-DEVD-CHO
appear to be independent of apoptosis. Inhibition of caspase-3 is a novel therapeutic strategy
to improve functional recovery of stunned myocardium. (J Am Coll Cardiol 2001;38:
2063–70) © 2001 by the American College of Cardiology
A significant reduction of coronary blood flow causes
myocardial ischemia and contractile dysfunction. The car-
diac dysfunction often persists for days, even after coronary
artery perfusion has been re-established. This scenario of
reversible post-ischemic contractile dysfunction is known as
myocardial stunning (1). Depressed contractility, with re-
duced maximal force generation, is a hallmark of stunning
(2–5).
Apoptosis is an evolutionary conserved process of pro-
grammed cell death in response to diverse stimuli, such as
cardiac development or hypoxia (6). Increased cardiomyo-
cyte apoptosis has been reported in patients with heart
failure and experimental myocardial infarction (MI) (7–10).
The caspase family of cellular proteases initiates and exe-
cutes apoptotic cell death (11). Caspase-3, a pivotal effector
caspase, is an essential protease of the apoptotic machinery.
Caspase-3 proteolytically cleaves a number of death sub-
strates and activates endonucleases, leading to internucleo-
somal deoxyribonucleic acid (DNA) fragmentation, a hall-
mark of apoptosis (12). Individual caspases differ in their
substrate recognition sequences, which has allowed genera-
tion of inhibitors like Ac-DEVD-CHO that specifically
inhibit caspase-3 (3). Ac-DEVD-CHO is a tetrapeptide
(Asp-Glu-Val-Asp) based on the caspase-3 substrate rec-
ognition motif, with an acetylate group coupled to its
N-terminal (for enhanced chemical stability) and an alde-
hyde group conjugated to its C-terminal (for irreversible
inactivation of the caspase-3 catalytic cysteine residue)
(13,14).
In a rabbit and rat model of MI, administration of a
broad-spectrum caspase inhibitor before infarction signifi-
cantly reduced the infarct size and rate of apoptotic cells in
the area at risk (9,10). However, it is unknown whether
caspase inhibitors functionally improve stunned myocar-
dium and whether they are effective when given after the
onset of myocardial ischemia. The latter would be more
relevant to the clinical situation.
Therefore, we investigated the effects of the caspase-3
inhibitor Ac-DEVD-CHO in an isolated working-heart rat
model of myocardial stunning. Our data suggest that inhi-
bition of caspase-3 reduces myocardial stunning when
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initiated after the onset of ischemia (I), but before reperfu-
sion (R). Thus, caspase-3 inhibition represents a novel
therapeutic strategy to improve contractile functional recov-
ery of stunned myocardium.
METHODS
Isolated working-heart rat model. Male, 4- to 6-week-old
Sprague Dawly rats were anesthetized with pentobarbital
(60 mg/kg intraperitoneally [IP]), heparinized (500 IU/100 g
body weight IP). The hearts were removed, and the aorta
was mounted onto a 1.4-mm cannula and attached to a
perfusion apparatus (Hugo Sachs Electronic). The hearts
were perfused with oxygenated (95% oxygen, 5% carbon
dioxide), noncirculating Tyrode’s solution (in mmol/l):
124.6 NaCl; 4.0 KCl; 2.2 CaCl2; 1.1 MgCl2; 24.9
NaHCO3; 0.3 NaH2PO4; and 11.1 glucose (pH 7.4) at a
perfusion pressure of 51 mm Hg. After equilibration for 15
min, the perfusion was switched to the anterograde
working-heart mode, with a preload of 11 mm Hg and an
afterload of 51 mm Hg. Aortic pressure was measured
through a pressure transducer (Hugo Sachs Electronic).
Left ventricular pressure (LVP) was measured by using a
microtipped catheter (SPR 407, 2F, Millar Instruments).
The maximal rise in LVP was obtained with an electronic
differentiation system (PLUGSYS, Hugo Sachs Electronic).
Aortic and coronary flow rates were measured by transonic
flow probes (Transonic Systems). Heart rate was monitored
by electrography (Hugo Sachs Electronic), and the hearts
were paced at 5 Hz.
Experimental groups and protocols. In 8 to 10 animals in
each experimental group, global low-flow ischemia was
induced by reducing the coronary flow to 10%, resulting in
a reduction of aortic pressure from 51 to 11 mm Hg.
Low-flow ischemia was maintained for 30 min, followed by
30 min of reperfusion. External heart power (EHP) per
gram of left ventricular (LV) wet weight was calculated:
EHPLV (mJ/g per min)  pressure – volume work/heart
rate. Dimethyl sulfoxide (DMSO; 0.01%; Sigma) as vehicle
or Ac-DEVD-CHO in 0.01% DMSO final (0.1 to
1 mol/l; Alexis) was started 15 min before ischemia or
5 min before reperfusion and given throughout the reper-
fusion period.
Immunoblotting. Tissue was homogenized in lysis buffer
(10 mmol/l tris-HCl, pH 8.0; 1% Triton X-100; 0.32 mol/l
sucrose; 5 mmol/l EDTA; and 1 mmol/l phenylmethylsul-
fonylfluoride), and proteins were separated by sodium
dodecyl sulfate/polyacrylamide gel electrophoresis (SDS/
PAGE), transferred to PVDF membranes and immuno-
blotted, as described (15), with the following primary
antibodies: anti-troponin I (clone C5), anti-mouse actin
(both Chemicon) or anti-caspase-3 (p17 subunit, Santa
Cruz Biotechnology). Bound antibodies were studied by
chemiluminescence (Amersham).
Caspase-3 and calpain enzymatic assays. Myocardial tis-
sue was homogenized as described previously, and 200 g of
protein was used in 700 l of caspase-assay buffer (100
mmol/liter HEPES, pH 7.5; 0.32 mol/l sucrose; 100
mmol/l NaCl; 0.1% CHAPS; 2 mmol/l dithiotreitol; 10
g/ml aprotinin; 10 g/ml leupeptin; and 10 g/ml pep-
statin A), with 0.24 mmol/l of DEVD-AFC as the fluoro-
genic caspase-3 substrate, as described (16). For measuring
calpain-like activity, 200 g of protein was used in 600 l of
calpain-assay buffer (60 mmol/l imidazol, pH 7.5; 5 mmol/l
L-cysteine; 0.2% Triton X-100; 5 mmol/l CaCl2; 5 mmol/l
dithiotreitol; 10 g/ml aprotinin; 10 g/ml leupeptin; and
10 g/ml pepstatin A), with 0.24 mmol/l of fluorogenic
calpain substrate I (Calbiochem). Purified calpain I (5 U;
Calbiochem) was used as indicated, and after 60 to 100 s,
calpain inhibitor I (Roche) or Ac-DEVD-CHO was added
to the reaction mixture, while the increase in fluorescence
was still linear.
Detection of apoptosis. The DNA strand breaks were
analyzed in situ using 5-m sections with terminal deoxy-
nucleotidyl transferase (TdT)-mediated dUTP-biotin nick
end-labeling (TUNEL), as described (15). Internucleoso-
mal DNA fragmentation (“DNA laddering”) was detected
by incubation of phenol-chloroform extracted DNA with 5
U of Klenow polymerase and 0.5 Ci of (-32P)-dCTP,
followed by gel electrophoresis, as described (16).
Statistical analysis. All data are presented as the mean
value  SEM. Comparisons were performed by analysis of
variance for comparison of multiple measurements or by the
paired or unpaired Student t test. A Bonferroni correction
for multiple comparisons was used to determine the level of
significance. A p value 0.05 was considered statistically
significant.
RESULTS
Ac-DEVD-CHO improves post-ischemic contractile re-
covery in a model of myocardial stunning of isolated
working hearts of rats. As an experimental model of
myocardial stunning, we used isolated working hearts of rats
(17). Figure 1A illustrates the experimental protocol: after
initial stabilization for 15 min, the hearts were treated with
Ac-DEVD-CHO (0.1 to 1 mol/l) or vehicle (0.01%
DMSO) for 15 min before ischemia (8 to 10 hearts per
experimental group). After 30 min of low-flow ischemia,
reperfusion was established for 30 min. For the first 15 min
of reperfusion, the hearts were perfused in the Langendorff
mode to allow for recovery. Then, perfusion was switched
back to the working-heart mode. Under these conditions,
Abbreviations and Acronyms
DMSO  dimethyl sulfoxide
DNA  deoxyribonucleic acid
LV  left ventricular
LVP  left ventricular pressure
MI  myocardial infarction
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the residual 10% coronary flow during ischemia largely
prevented MI (17).
In the control group, cardiac output, external heart
power, (LV) developing pressure, myocardial contractility
and aortic and coronary flow (data not shown) severely
decreased during the ischemic period and remained de-
pressed during reperfusion (Fig. 1B). Treatment of isolated
hearts with 0.1 to 1 mol/l of Ac-DEVD-CHO (starting
15 min before ischemia) did not affect cardiac performance
at baseline or during ischemia. However, Ac-DEVD-CHO
dose-dependently and significantly (p  0.05 for 1 mol/l)
improved the contractile recovery of post-ischemic myocar-
dium. Just 1 mol/l of Ac-DEVD-CHO significantly
enhanced cardiac output, external heart power, LV devel-
oping pressure, myocardial contractility (Fig. 1B) and aortic
and coronary flow (data not shown).
Figure 2 shows that only 20% to 45% (calculated values
relative to pre-ischemic baseline value) of post-ischemic
recovery of the various variables was observed in the vehicle-
treated group. This indicates severe cardiac dysfunction,
even after restoration of perfusion. Treatment with 1 mol/l
of Ac-DEVD-CHO increased the relative recovery of all
variables to 60% to 85% of the pre-ischemic values (Fig. 2).
Ac-DEVD-CHO is equally effective when administered
before reperfusion. To investigate whether Ac-DEVD-
CHO protects the myocardium from stunning when ad-
ministered after the onset of ischemia, Ac-DEVD-CHO
(1 mol/l) was started 5 min before reperfusion. This
scenario more closely resembles the common clinical situa-
tion of patients presenting with acute coronary syndromes.
As shown in Figure 2, the group treated with 1 mol/liter
of Ac-DEVD-CHO, started 5 min before reperfusion, led
Figure 1. The caspase-3 inhibitor Ac-DEVD-CHO improves contractile recovery of isolated working hearts of rats exposed to ischemia and reperfusion.
(A) Schematic diagram of the experimental set-up. (B) Effects of the caspase-3 inhibitor Ac-DEVD-CHO (0.1 to 1 mol/liter) or vehicle (0.01% DMSO)
on cardiac output (CO), external heart power per gram of LV wet weight (EHPLV), left ventricular developing pressure (LVDP) and contractility
(dp/dtmax). Data are presented as the mean value  SEM; there are 8 to 10 animals per group. *p  0.05 versus vehicle-treated group.
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to a significantly (p  0.05) improved post-ischemic recov-
ery of cardiac performance, compared with the vehicle-
treated group. Specifically, Ac-DEVD-CHO started 5 min
before reperfusion improved cardiac output, external heart
power, LV developing pressure, myocardial contractility and
aortic and coronary flow to a similar degree, compared with
Ac-DEVD-CHO started 15 min before ischemia (Fig. 2).
Ac-DEVD-CHO blocks ischemia/reperfusion-induced
activation of caspase-3. Next, we investigated the effects
of ischemia/reperfusion and Ac-DEVD-CHO on the acti-
vation of caspase-3. Caspase-3 exists as an inactive zymogen
of 32 kD and is activated by proteolytic processing into p17
and p12 subunits (11,12).
Immunoblotting of rat heart extracts for the p17 subunit
of caspase-3 (Fig. 3A, left) detected only the inactive 32-kD
zymogen in nonischemic hearts. Ischemia/reperfusion
caused caspase-3 activation, with the appearance of the
processed p17 subunit in the vehicle group. Treatment with
Ac-DEVD-CHO before reperfusion almost completely
blocked activation of caspase-3 induced by ischemia/
reperfusion.
To determine catalytic activity of caspase-3 in rat heart
extracts, we used a fluorogenic caspase-3 substrate (Fig. 3A,
right). When compared with the control group, caspase-3–
like activity was more than fivefold increased by ischemia/
reperfusion in the vehicle-treated group (p  0.05). Treat-
ment with Ac-DEVD-CHO from 5 min before reperfusion
abolished activation of caspase-3, with proteolytic activity
remaining close to baseline levels (p  0.05 vs. vehicle-
treated group).
These results demonstrate that Ac-DEVD-CHO is able
to block the ischemia/reperfusion-induced activation of
caspase-3.
Effects of Ac-DEVD-CHO on apoptosis. Increased ap-
optosis has been implicated in MI (9,10). Because Ac-
DEVD-CHO can block apoptosis in various cell types (12),
we determined the rate of apoptotic cells by TUNEL
staining and internucleosomal DNA fragmentation.
As shown in Figure 3B, we detected single TUNEL-
positive cells in the nonischemic myocardium, as well as in
the vehicle-treated and Ac-DEVD-CHO–treated myocar-
dium subjected to ischemia/reperfusion. The TUNEL-
positive cells appeared to be mostly cardiomyocytes. Quan-
titative analysis (5 sectors of 500 cells/sector; n  4 hearts
in each group) revealed a significant (p  0.05) increase in
the number of TUNEL-positive cells in both the vehicle-
treated (0.38  0.18%) and Ac-DEVD-CHO–treated
(0.42 0.31%) groups, compared with nonischemic control
group (0.05  0.03%).
This increase in the rate of myocardial apoptosis during
ischemia/reperfusion was confirmed by the internucleoso-
mal DNA fragmentation assay. Compared with the non-
ischemic control group, ischemia/reperfusion caused an
increase in DNA strand breaks, with the typical “ladder”
pattern (Fig. 3B, right). The ischemia/reperfusion-induced
increase in apoptosis was similar in the vehicle-treated and
Ac-DEVD-CHO–treated groups.
Effects of Ac-DEVD-CHO on troponin I degradation
and calpain activity. Because the beneficial effect of Ac-
DEVD-CHO on contractile recovery was largely indepen-
dent of apoptosis, we investigated whether Ac-DEVD-
CHO may inhibit other cysteine proteases, such as calpain.
Because calpain-mediated cleavage of the thin-filament
regulatory protein troponin I has been suggested as a
molecular mechanism of stunning (1), we investigated the
effects of Ac-DEVD-CHO on troponin I degradation and
calpain activity.
Immunoblotting with an anti–troponin I antibody
showed increased appearance of the characteristic troponin
I fragment in vehicle-treated and Ac-DEVD-CHO–
treated hearts subjected to ischemia/reperfusion (Fig. 4A).
However, Ac-DEVD-CHO started 5 min before reperfu-
sion did not quantitatively alter the troponin I degradation.
Using a fluorogenic calpain substrate, we were unable to
Figure 2. Ac-DEVD-CHO is effective when given 5 min before reperfu-
sion. The effect of Ac-DEVD-CHO on contractile recovery is shown,
calculated as percent recovery compared with baseline (pre-ischemic) values
of left ventricular developing pressure (LVDP), contractility (dp/dtmax),
aortic flow (AF), coronary flow (CF), cardiac output (CO) and external
heart power (EHP). Data are presented as the mean value  SEM; there
are 8 to 10 animals in each group. Ac-DEVD-CHO was started 15 min
before ischemia (top) or 5 min before reperfusion (bottom). Note the
similar beneficial effect of Ac-DEVD-CHO on the relative recovery. *p 
0.05 versus vehicle-treated group. Open bars  0.01% DMSO; solid bars
 1 mol/l of Ac-DEVD-CHO.
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reproducibly detect measurable calpain-like proteolytic ac-
tivity in any of the rat hearts (data not shown). To address
a potential nonspecific effect of Ac-DEVD-CHO on cal-
pain, we determined the effects of Ac-DEVD-CHO on
purified calpain I in vitro. The addition of calpain to its
substrate caused a linear increase in fluorescence (Fig. 4B).
While the increase was still linear, calpain inhibitor I or
Ac-DEVD-CHO was added. Although 100 nmol/l of
calpain inhibitor I almost completely inhibited calpain I, the
same concentration of Ac-DEVD-CHO had little inhibi-
tory effect. Quantitative evaluation of the remaining cata-
lytic activity after addition of the inhibitor (Fig. 4C) showed
that the cysteine protease calpain could be principally
inhibited by the aldehyde Ac-DEVD-CHO at higher
concentrations (1 mol/l). However, 10-fold higher con-
centrations of Ac-DEVD-CHO were needed to achieve an
equal inhibition of calpain, compared with calpain inhibitor
I. Taken together, these results indicate that, in vivo,
Ac-DEVD-CHO does not act primarily through calpain
inhibition.
Figure 3. Ac-DEVD-CHO blocks ischemia/reperfusion (I/R)-induced caspase-3 activation but not apoptosis. (A, left), Immunoblotting of rat hearts with
an antibody against the p17 subunit of caspase-3; three independent experiments are shown. Arrowheads indicate the molecular weight of the inactive
zymogen (32 kD) and the processed, active subunit (17 kD). (A, right), Caspase-3–like proteolytic activity of rat hearts (percent increase relative to the
proteolytic activity in control hearts), as measured with a fluorogenic substrate of caspase-3. *p  0.05. (B, left), Representative photomicrographs of
myocardial sections stained with the TUNEL technique to detect apoptotic cells in situ in a nonischemic control heart (top), a vehicle-treated heart
subjected to ischemia/reperfusion (middle) or an Ac-DEVD-CHO-treated heart subjected to ischemia/reperfusion (bottom). Arrows indicate
TUNEL-positive cells. Magnification 200. (B, right) Autoradiogram of radioactively labeled DNA strand breaks, followed by agarose gel electrophoresis;
results from four independent samples in each group. Equal loading was verified by ethidium bromide staining. Note the internucleosomal DNA
fragmentation (“ladder pattern”) induced by ischemia/reperfusion.
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DISCUSSION
The caspase-3 inhibitor Ac-DEVD-CHO significantly im-
proves post-ischemic contractile recovery of isolated work-
ing hearts of rats. Interestingly, Ac-DEVD-CHO was
effective even when given after the onset of low-flow
ischemia. The effects of caspase-3 inhibition appeared to be
largely independent of cardiomyocyte apoptosis.
Myocardial stunning and caspase-3 activation. The role
of apoptosis in the pathogenesis of myocardial stunning is
unknown. Because caspase-3 is a key protease that executes
apoptosis, we investigated whether caspase-3 inhibition
reduces myocardial stunning in an isolated working-heart
rat model. This model is well established and allows
study of myocardial contractility in the intact heart,
independent of compounding factors, such as sympa-
thetic activity and activation of an immune response (17).
Indeed, caspase-3 was activated in our model of myocar-
dial stunning. Thus, our data confirm and extend two
recently published studies demonstrating activation of
caspase-3 in a rat and rabbit model of MI (9,10). As
hypothesized, Ac-DEVD-CHO was able to block the
Figure 4. Effects of DEVD-CHO on troponin I degradation and calpain activity. (A) Immunoblots of rat hearts with an antibody against troponin I (upper
blots) or actin (lower blots). Arrowheads indicate the molecular weight. The top right arrow indicates full-length troponin I; the lower arrow indicates
the major degradation product. (B) Effects of 0.1 mol/l of calpain inhibitor I (left) or Ac-DEVD-CHO (right) on the catalytic activity of 5 U of calpain
I, as measured in vitro with a fluorogenic calpain I substrate. (C) Quantitative evaluation of the percent activity after addition of the inhibitor, compared
with the activity measured before addition of the inhibitor. Data are presented as the mean value  SEM from three independent measurements for each
data point.
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ischemia/reperfusion-induced activation of caspase-3 in
our experimental model.
Ac-DEVD-CHO functionally improves stunned myo-
cardium. In contrast to the vehicle, the caspase-3 inhibitor
Ac-DEVD-CHO dose-dependently and significantly im-
proved post-ischemic contractile recovery. Just 1 mol/l led
to almost a doubling of all contractile variables to 60% to
85% of the pre-ischemic values. These good recovery rates
principally achievable with an appropriate pharmacologic
intervention also demonstrate that low-flow ischemia/
reperfusion in our model causes mainly myocardial stunning
but little if any MI. Importantly, Ac-DEVD-CHO was
equally potent in reducing myocardial stunning when given
5 min before reperfusion, instead of before the induction of
ischemia. This scenario being given resembles the clinical
situation.
Myocardial stunning and apoptosis. Although the bene-
ficial effect of caspase inhibitors in experimental MI has
been attributed to a reduced rate of apoptosis (7,10), our
data do not support a role for the inhibition of apoptosis as
the mechanism by which Ac-DEVD-CHO acts on the
contractile recovery of stunned myocardium. Ac-DEVD-
CHO neither reduced the number of TUNEL-positive
cells, nor the amount of internucleosomal DNA fragmen-
tation. Although ischemia/reperfusion-induced caspase-3-
activation was associated with a minor increase in the
number of apoptotic cells and fragmented DNA, there was
no significant effect of DEVD-CHO on the degree of
apoptosis. Thus, apoptosis of cardiac myocytes in this
experimental setting seems to be mediated by a caspase-
independent pathway. Indeed, a recent study suggests that
other signalling pathways can induce apoptosis independent
of the caspase cascade (18). Moreover, it remains to be
clarified whether an increase of apoptosis of 0.3% has any
significant outcome with regard to the early functional
integrity of the heart. Therefore, the profound improvement
in post-ischemic contractile recovery by the caspase-3 in-
hibitor Ac-DEVD-CHO appears to be independent of
apoptosis in the experimental setting used. These findings
indicate that the integrity of the contractile apparatus may
be adversely affected by caspase-3 activation in the myocar-
dium during stunning.
Degradation of contractile proteins during myocardial
stunning. Selective troponin I degradation has been re-
ported in some (1–5,19), but not all (20), models of
myocardial stunning. Transgenic overexpression of the ma-
jor proteolytic troponin I product in the heart is sufficient to
recapitulate many aspects of myocardial stunning (21).
Subsequent studies suggested calpain-mediated cleavage of
troponin I as an underlying mechanism (2–5,19), and
calpain inhibitor I is able to reduce infarct size (22) and
improve myocardial stunning (23). Because Ac-DEVD-
CHO may inhibit other cysteine proteases, such as calpain,
we investigated whether Ac-DEVD-CHO may inhibit
troponin I degradation. Consistent with published reports
(2–5,19), ischemia/reperfusion in isolated working hearts of
rats resulted in partial troponin I degradation, which was
not quantitatively affected by Ac-DEVD-CHO. In vitro,
purified calpain could be inhibited by Ac-DEVD-CHO.
However, 1 mol/l of Ac-DEVD-CHO achieved only
partial calpain inhibition, indicating that it acts in vivo,
primarily through pathway(s) other than calpain inhibition.
However, we cannot exclude that Ac-DEVD-CHO exerts
some of its beneficial effects by partial calpain inhibition.
Calpain or other proteinase(s) may play a pathogenic role in
our model, because we achieved only incomplete recovery
with Ac-DEVD-CHO.
Alternatively, Ac-DEVD-CHO may inhibit cleavage of
other contractile proteins. Through a data bank search with
caspase cleavage motifs, we identified a putative caspase
cleavage site (DEVD63) in cardiac troponin C (12). How-
ever, immunoblots of rat hearts with troponin C antibodies
did not show any troponin C degradation during ischemia-
reperfusion (data not shown). Further experiments will be
required to identify the molecular target(s) of caspase
activation during stunning.
Conclusions. Taken together, in an isolated working-heart
rat model of myocardial stunning, inhibition of ischemia/
reperfusion-induced caspase-3 activation by Ac-DEVD-
CHO results in a substantial improvement of post-ischemic
contractile recovery. The observed effects appear to be
independent of suppression of apoptosis, but most likely
involve both caspase and calpain inhibition. Regardless of
the underlying mechanism(s), the use of a caspase-3 inhib-
itor represents a potentially clinically relevant, novel thera-
peutic strategy to reduce myocardial stunning.
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